XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss Per Share
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share

Note 11 — Net Loss Per Share

 

The “Net loss per share basic and diluted” for the respective periods indicated - is as follows:

 

   2021   2020   2021   2020 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
Numerator                    
Net loss  $(6,956,619)  $(2,021,677)  $(16,772,393)  $(5,548,873)
                     
Denominator                    
Weighted average common shares outstanding, basic and diluted   14,114,707    14,114,707    14,114,707    14,114,347 
                     
Net Loss per share                    
Net loss per share - basic and diluted  $(0.49)  $(0.14)  $(1.19)  $(0.39)

 

Basic weighted-average number of shares of common stock outstanding for the three and nine months ended September 30, 2021 and 2020 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows:

 

   September 30, 
   2021   2020 
Lucid Diagnostics Inc. 2018 Equity Plan:          
- stock options   975,942    975,942 
- unvested restricted stock awards   1,813,135    — 
Stock options not granted under a plan   423,300    423,300 
Total   3,212,377    1,399,242